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Ashok Srinivasan,1,5 Chong Wang,4 Jie Yang,4 Jerry L. Shenep,3,5
Wing H. Leung,1,5 Randall T. Hayden2Parainfluenza virus (PIV) infections cause significant mortality in adults undergoing hematopoietic stem cell
transplantation (HSCT). Children are more prone to PIV infections than adults; however, data on the epide-
miology of these infections in children undergoing HSCT are limited. This study examined the incidence of
symptomatic PIV infections, risk factors for lower respiratory tract infection (LRTI), and the impact on mor-
tality afterpediatricHSCT.A total of 1028childrenwhounderwentHSCTbetween1995 and2009were studied.
PIV infections were detected in 46 of the 738 patients tested for respiratory infection (6.2%). PIV infection was
themost common symptomatic respiratory viral infection in this population. Onmultivariate logistic regression
analysis, receipt of an allogeneic transplant (P\.0001) and total body irradiation–based conditioning (P\.0001)
were associated with increased risk of acquiring symptomatic PIV infection. Of the 46 HSCT patients with PIV
infection, 18 (39%) had an LRTI. LRTIwas associatedwith PIV infection in the first 100days post-HSCT (P5.006),
useof steroids (P5.035), and absolute leukocyte count (ALC)\100cells/mL at theonsetof infection (P\.0001).
An ALCof\500 cells/mLwas associated with prolonged viral shedding (P5.045). Six (13%)HSCT patients died
of PIV infection.Mortality was associatedwith African-American ethnicity (P5.013), LRTI (P5.002), use of ste-
roids (P \ .0001), mechanical ventilation (P \ .0001), and ALC \100 cells/mL at the onset of infection
(P5 .01). PIV infection causes significant morbidity and mortality in children undergoing HSCT.
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The human parainfluenza virus (PIV), which be-
longs to the family Paramyxoviridae, is an enveloped,
single-stranded, RNA virus that causes upper respira-
tory tract infections (URTIs) and lower respiratory tract
infections (LRTIs) in children andadults.PIV infections
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6/j.bbmt.2011.03.001adults undergoing hematopoietic stem cell transplanta-
tion (HSCT), with a 180-day mortality as high as 75%
[1]. In the largest studyofPIV infections in adults under-
goingHSCT to date, the only risk factor for developing
a PIV infection was transplantation from an unrelated
donor [1]. Use of corticosteroids for graft-versus-host
disease (GVHD) was associated with progression to
LRTI.Mortalitywas increased in adultswhohadunder-
gone transplantation within 100 days [1-3] and by the
presence of copathogens [1], URTI [1], LRTI [1,4],
and the need for mechanical ventilation [1].
Children are more prone to PIV infections than
adults, and PIV is the second leading (after respiratory
syncytial virus [RSV]) cause of URTI and LRTI in
those under age 5 years [5]. The rate of hospitalization
for PIV infection in this group of children may be
greater than that due to influenza viruses [5]. Data
on the epidemiology of PIV infections in children un-
dergoing HSCT are limited, however.
This study sought to retrospectively determine the
incidence of symptomatic PIV infections in a large co-
hort of children undergoing HSCT at our institution.
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on mortality after HSCT were studied.PATIENTS AND METHODS
Patient Population
This retrospective cohort study included 1028
children who underwent allogeneic or autologous
HSCT over a 15-year period (January 1995 through
December 2009) at St Jude Children’s Research Hos-
pital (SJCRH). A total of 738 children were tested for
respiratory infections. The study was approved by
SJCRH’s Institutional Review Board.
SJCRH is a referral cancer hospital for children.
Patients who have undergone HSCT are followed
for a period of 10 years after transplantation or until
age 18 years, whichever is later. Virologic records
were reviewed to identify HSCT recipients in whom
PIV 1-4 was detected in respiratory tract secretions
by culture, direct fluorescent antibody (DFA) testing,
or polymerase chain reaction (PCR). The medical re-
cords review included analysis of clinical variables, in-
cluding age, race, sex, underlying malignancy, date of
onset of respiratory symptoms, duration of viral shed-
ding, whether infection was a URTI or an LRTI that
was either hospital- or community-acquired, presence
of fever, need for oxygen ormechanical ventilation, ad-
mission to an intensive care unit, mortality, absolute
neutrophil count (ANC), absolute lymphocyte count
(ALC) at the time of infection, and copathogens.
Virology and Microbiology Procedures
Anasopharyngeal swab orwash for culture and viral
DFA staining was performed in patients with clinically
suspectedURTI or LRTI. Respiratory samples also in-
cluded bronchoalveolar lavage (BAL), tracheal secre-
tions, lung biopsy, and autopsy specimens. All patients
with LRTI underwent BAL. Samples were inoculated
into tissue culture containing rhesus monkey kidney,
A549, and Madin-Darby canine kidney (MDCK) cells.
Respiratory cultures were kept for 14 days before being
reported as negative. A virus that caused hemadsorption
with guinea pig red cells on day 7 and 14 or a cytopathic
effect at any time was confirmed as PIV 1-4 using type-
specific respiratory DFA smears prepared using com-
mercially available type-specific antisera against PIV
1-4 (Diagnostic Hybrid, Athens, OH). PCR was per-
formed on respiratory samples obtained after February
2007, using a laboratory-developed test panel of indi-
vidual real-time PCR assays targeting PIV 1-3, which
were run on a SmartCycler real-time PCR instrument
(Cepheid, Sunnyvale, CA).
Definitions
PIV infection was defined as a URTI when signs
and symptoms were consistent with the diagnosis,with normal chest examination and chest roentgeno-
gram results. PIV infection was defined as an LRTI
when symptoms were accompanied by signs on lung
auscultation and a new pulmonary infiltrate as defined
by a plain chest radiograph, high-resolution computed
tomography (CT), or both, and unexplained by a non-
infectious etiology. The day of onset of PIV infection
was defined as the day when the positive diagnostic
sample was collected. Mortality was considered attrib-
utable to PIV if the patient died from an LRTI as a re-
sult of respiratory failure, with isolation of PIV from
respiratory secretions and with no other ascertainable
cause. The presence of a copathogen was defined by
the isolation or detection of pathogenic bacterial or
fungal species or by the identification of other oppor-
tunistic pathogens in addition to PIV from any site.
Hospital-acquired (HA) infections were defined as
symptomatic PIV infections occurring 7 days or more
after admission to the inpatient unit. Duration of viral
shedding was defined as the interval between the day of
the first positive culture or diagnostic test and the first
negative culture or diagnostic test. Recurrent infec-
tions were identified by isolation or detection of PIV
from the same patient 14 or more days after the last
negative culture or diagnostic test. Only the first infec-
tion from each patient and the first transplantation
were included in the analyses. The day of engraftment
after HSCT was defined as the first of 3 consecutive
days of achieving an ANC .500 cells/mL. Assessment
of GVHD was based on consensus criteria [6].
Management
Children diagnosed with PIV infection were placed
in respiratory isolation.Nasopharyngeal swabsorwashes
were obtained onceweekly inmost patients to document
clearance of the virus. At the discretion of the treating
physician, ribavirin was administered at a dose of 2 g
(60 mg/mL) by intermittent aerosolization for 2 hours,
3 times aday, for up to7days.Treatmentwithantibiotics
and antifungals was provided as indicated.
Patients were isolated post-HSCT in individual
rooms with positive pressure with respect to the hall-
way and high-efficiency particulate air filtration. Visi-
tors were screened and strongly encouraged to
perform hand hygiene before and after every patient
contact. Intravenous immune globulin was routinely
given weekly to all patients until day 1100 post-
HSCT, to maintain a trough serum concentration
.400 mg/dL. Prophylaxis against RSV was provided
monthly with palivizumab or RespiGam (MedImmune,
Gaithersburg, MD) during the RSV season for trans-
plant recipients under age 2 years.
Statistical Analysis
Descriptive statistics were obtained for the demo-
graphic variables of children with PIV infection who
1522 Biol Blood Marrow Transplant 17:1520-1527, 2011A. Srinivasan et al.had undergone HSCT. The marginal association be-
tween PIV infection and independent variables were
determined using the Fisher exact test and the
Kruskal-Wallis test. Furthermore, when appropriate,
exact multiple logistic regression models were used
to investigate the independent association of one factor
after controlling for other variables. The Wilcoxon
rank sum test was used to compare continuous vari-
ables between 2 groups. All analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC).RESULTS
Incidence of Symptomatic PIV Infections
PIV infection was documented in 46 of the 738
HSCT patients (6.2%) tested between January 1995
and December 2009. PIV infection was the most com-
mon respiratory viral infection in our cohort during
this 15-year period, followed by adenovirus (39 pa-
tients; 5.3%), influenza A (36; 4.9%), cytomegalovirus
(CMV) (33; 4.5%), RSV (29; 3.9%), herpes simplex vi-
rus (19; 2.6%), influenza B (15; 2%), rhinovirus (7;
1%), human metapneumovirus (2;\1%), and human
enterovirus (1;\1%).
PIV-3 accounted for themajority of PIV infections
(30/46; 65%). PIV-1 was isolated in 8 patients (17%),
PIV-2 was isolated in 5 patients (11%), and PIV-4
was isolated in 2 patients (4%). The isolate was not
typed in 1 patient. PIV-3 infections occurred through-
out the year, peaking in the spring and summer (30/45;
66%), whereas .60% of the PIV-1, -2, and -4 infec-
tions occurred in the fall and winter (Figure 1). PIV-
1 was seen predominantly in odd-numbered years,
including 1995, 1997, 2001, 2003, and 2009. PIV-2
also occurred predominantly in odd-numbered years,Figure 1. Monthly distribution of the incidence of symptomatic PIV respirato
and 2009.including 1997, 1999, and 2003. There were 21 PIV
infections between 1995 and 1999, 15 between 2000
and 2004, and 10 between 2005 and 2009, with no trend
in frequency over time observed (P5 .31). No apparent
outbreaks of infectionwere observed.Of the 46 patients,
33 (72%) had a community-acquired (CA) infection,
and 13 (28%) had an HA infection. These were inter-
spersed among CA infections with no evidence of clus-
tering. A single cluster of 3 CA infections occurred over
1 month during the study period.Risk Factors for Development of Symptomatic
PIV Infection
The characteristics of the HSCT recipients with
and without PIV infection are summarized in Table 1.
The entire cohort of 1028 patients was followed for
a total of 3472 patient-years, giving an incidence of
13.2 cases of symptomatic PIV infection per 1000
patient-years of observation. The median age of the
children at the time of infection was 5 years, 6 months
(range, 8 months to 20 years, 8 months). Of the 46
patients with PIV infection, 5 (11%) were age #2
years, 23 (50%) were age 2-10 years, 16 (35%) were
age 10-18 years, and 2 (4%) were age 18-21 years.
Univariate logistic regression analysis revealed
that receipt of allogeneic HSCT (P5 .0016) and total-
body irradiation (TBI; P 5 .0003) were significantly
associated with PIV infection. An underlying diagnosis
of leukemia (P 5 .04) was of marginal significance
(Table 1). On multivariate logistic regression analysis,
patients who underwent allogeneic HSCT (P\ .0001)
and those who received TBI (P\ .0001) were more
likely to acquire PIV infection. Patients with an under-
lying diagnosis of a solid tumor (P5 .005) and GVHD
(P 5 .006) were less likely to have PIV infection. Age,ry infections in children who underwent HSCTat SJCRH between 1995
Table 1. Characteristics of the HSCT Recipients with and without Symptomatic PIV Infection
Characteristic
Study
Cohort
(n 5 1028)
Children without
PIV Infection
(n 5 982)
Children with
PIV Infection
(n 5 46) P Value
Odds Ratio (95%
Confidence Interval)
Median age, years 8.6 8.6 5.5 .20
Males, n (%) 630 (61) 602 (61) 28 (61) .95 1.0 (0.56-1.87)
Race, n (%)
White 752 (73) 722 (74) 30 (65) .96 1.34 (0.62-2.87)
African-American 171 (17) 162 (16) 9 (20)
Others 105 (10) 98 (11) 7 (6)
Diagnosis, n (%)
Leukemia 497 (48) 468 (48) 29 (63) .04 1.87 (1.0-3.5)
Lymphoma 94 (9) 92 (9) 2 (4)
Myelodysplastic syndrome 46 (4) 43 (4) 3 (7)
Solid tumors 253 (25) 251 (26) 2 (4) .005 0.13 (0.03-0.6)
Hematologic disorders 62 (6) 56 (6) 6 (13)
Immunologic disorders 44 (4) 40 (4) 4 (9)
Metabolic disorders 32 (3) 32 (3) 0
Donor type, n (%)
Autologous 333 (32) 329 (34) 4 (9) .001 5.3 (1.89-14.88)
Allogeneic 695 (68) 653 (66) 42 (91)
Unrelated 278 (22) 255 (21) 23 (50) .40 0.69 (0.30-1.47)
Matched unrelated 225 (22) 202 (21) 23 (50)
Mismatched unrelated 53 (5) 53 (5) 0
Sibling related 214 (17) 204 (17) 10 (22)
Matched sibling 207 (16) 197 (16) 10 (22)
Mismatched sibling 7 (1) 7 (1) 0
Haploidentical 194 (15) 186 (15) 8 (17)
Cord blood 9 (1) 8 (1) 1 (2)
CMV-positive recipient, n (%) 543 (52) 524 (55) 19 (41) .11 0.61 (0.34-1.12)
Conditioning, n (%)
Total-body irradiation 458 (45) 425 (43) 33 (72) .0003 0.30 (0.16-0.58)
Nonmyeloablative 27 (3) 25 (2) 2 (4) .46 0.57 (0.13-2.50)
Myeloablative 1001 (98) 957 (97) 44 (95)
GVHD
Acute, n (%) 267 (26) 259 (26) 8 (17) .006 0.33 (0.15-0.72)
Grade I-II, n 205 199 6
Grade I-IV, n 62 60 2
Chronic, n (%) 120 (12) 120 (12) 0
Limited, n 70 70 0
Extensive, n 50 50 0
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-versus-host disease.
Biol Blood Marrow Transplant 17:1520-1527, 2011 1523Parainfluenza Virus Infectionssex, ethnicity, donor type, recipient CMV positivity,
myeloablative conditioning, and presence of GVHD
were not significantly associated with symptomatic
PIV infection (Table 1).
Clinical Features of Symptomatic PIV Infection
Of the 46 patients with PIV infection, 28 (61%)
presented with a URTI with no evidence of LRTI.
The most common symptoms were cough and rhinor-
rhea, accompanied by fever in only 1 patient. One pa-
tient with URTI presented with croup. Eighteen
patients (39%) had signs of LRTI on lung ausculta-
tion, with LRTI confirmed by chest radiography in
14 patients, showing unilateral alveolar infiltrates in
3 patients and bilateral interstitial infiltrates in 11.
In the 4 patients with normal chest radiography find-
ings, chest CT revealed bilateral interstitial infiltrates
in 2 patients and multiple bilateral lung nodules in
the other 2. Sinusitis as confirmed by CT was present
in 6 patients with LRTI and in 3 patients with URTI.
Fever accompanied LRTI in 7 patients (39%). LRTI
was preceded by URTI in all but 1 patient.Diagnosis of PIV Infection
The median duration between onset of symptoms
and diagnosis was 2 days (range, 1-7 days). Themedian
duration of viral shedding evaluated in 32 patients who
had at least one negative follow-up test was 8 days
(range, 2-38 days). The duration of viral shedding
was not significantly different between patients with
a URTI and those with an LRTI (P 5 .59). Of the re-
maining 14 patients, 4 did not have negative follow-up
testing because they died from the infection and 10 did
not undergo follow-up testing. For diagnosis of the
initial infection, the virus was isolated from culture
in all but 1 patient, who was identified by PCR only.
A positive DFA result was obtained with the culture
in 18 patients (39%). PCR tested positive with culture
in all 6 patients in whom both methods were used. Co-
pathogens were identified from the respiratory secre-
tions in 8 patients (17%), including adenovirus in 3
patients and Candida parapsilosis, herpes simplex virus,
Pseudomonas aeruginosa, and RSV in 1 patient each.
CMV viremia and adenoviremia were seen in 1 patient
each. Two patients had recurrent infections with
1524 Biol Blood Marrow Transplant 17:1520-1527, 2011A. Srinivasan et al.a different serotype occurring at 8 months and 4
months, respectively, after the initial infection.Table 3. Risk Factors for Mortality from Symptomatic PIVRisk Factors for LRTI
Thirteen patients developed a PIV infection less
than 30 days post-HSCT; 10 of these infections were
LRTI. Another 13 patients developed a PIV infection
at more than 1 year post-HSCT; 5 of these infections
were LRTI. The other cases of PIV infection were dis-
tributed proportionately in the periods 30-100 days,
100-180 days, and 6 months to 1 year post-HSCT.
Infection acquired before 100 days post-HSCT (P 5
.006) and the use of corticosteroids at the time of onset
of infection (P5 .035; Table 2) were significantly asso-
ciated with LRTI. Steroids were used to treat acute
GVHD of grade II-III severity in 8 patients. GVHD
was limited to the skin in 4 patients, to the gut in 1
patient, to both the skin and liver in 2 patients, and
to the skin and gut in 1 patient. Two other patients re-
ceived steroids for engraftment syndrome. Eight pa-
tients received steroids at a dose of 2 mg/kg/day, and
2 patients received steroids at a dose of 0.5 mg/kg/
day. Other factors that increased the risk for LRTI in-
cluded ANC\500 cells/mL (P\ .0001), ALC\100
cells/mL (P\ .0001), and ALC\500 cells/mL (P 5
.002) at the time of infection (Table 2).
Patients with an ALC \500 cells/mL also had
a more prolonged duration of viral shedding, with
a median of 14 days (range, 2-38 days), compared
with a median of 7 days (range, 2- 35 days) in patients
with an ALC.500 cells/mL (P5 .045). Age, race, sex,
season of infection, underlying diagnosis, remission
status, transplant and donor type, donor CMV status,
presence of GVHD, and PIV serotype were not asso-
ciated with LRTI. Pulmonary function testing per-
formed in 10 of the 12 patients with LRTI who had
survived for 1 year after the episode demonstrated no
abnormalities in 8 patients, decreased diffusion capac-
ity in 1 patient, and restrictive lung disease in 1 patient.
Of the 46 patients with PIV infection, 32 (70%) re-
ceived TBI-based conditioning. LRTI was diagnosed
in only 11 of the 32 patients (34%). Three of theseTable 2. Risk Factors for LRTI from Symptomatic PIV
Infections
Characteristic
LRTI
(n 5 18)
URTI
(n 5 28) P Value
Infection <100 days
posttransplantation
13 8 .006
Infection >100 days
posttransplantation
5 20
Use of steroids before infection 7 3 .035
No steroids before infection 11 25
ANC <500 cells/mL 9 1 <.0001
ANC >500 cells/mL 9 27
ALC <100 cells/mL 12 3 <.0001
ALC >100 cells/mL 6 25patients succumbed to the infection. Of the 8 surviving
patients, 2 had lung function abnormalities as noted
earlier at 1 year after transplantation, with evidence
of decreased diffusion capacity in 1 patient and
restrictive lung disease in the other.
Risk Factors for Mortality in Patients with
Symptomatic PIV Infections
Mortality was attributed to PIV infection in 6 pa-
tients (13%). Of these 6 patients, 4 (67%) were
African-American (AA), compared with 10 (22%) in
the study group (P 5 .013). Children of AA ethnicity
were more likely to have received steroids before the
onset of infection (P 5 .008). The presence of
GVHD (P 5 .04) and ANC\100 cells/ mL (P 5 .04)
was found to have a marginally significant association
with PIV infection in the AA group. The rates of
LRTI (P 5 0.12), infection occurring before 100
days post-HSCT (P 5 .71), and ALC\100 cells/mL
(P 5 .24) were not significantly different in AA chil-
dren compared with non-AA children.
All of the deceased patients were recipients of allo-
geneic HSCT, had LRTI, and died of respiratory fail-
ure. BAL fluid was the source of the respiratory sample
in all of these patients. Mechanical ventilation was ini-
tiated in the 6 patients at a median duration of 2 weeks
from the onset of symptoms (range, 2 days to 4 weeks).
Death occurred at a median duration of 3 weeks after
ventilation (range, 2-6 weeks). LRTI (P 5 .002) and
the need for mechanical ventilation (P\ .0001) were
significantly associated with mortality (Table 3). Acute
GVHD was seen in 4 of the 6 deceased patients, and 5
patients received steroids to manage GVHD. Steroid
use at the onset of infection was associated with mor-
tality (P\ .0001), as was an ALC\100 cells/mL at
the onset of infection (P5 .01; Table 3). Age, sex, do-
nor type, donor CMV status, time of infection after
HSCT, underlying disease, type of conditioning, dura-
tion of viral shedding, and presence of copathogens
were not associated with mortality. Infection wasInfections
Characteristic
Mortality
P Value
Yes
(n 5 6)
No
(n 5 40)
African-American 4 5 .013
White 2 28
Other 0 7
LRTI 6 12 .002
URTI 0 28
Mechanical ventilation 6 0 <.0001
No mechanical ventilation 0 40
Use of steroids before infection 5 4 <.0001
No steroids before infection 1 36
ALC <100 cells/mL 5 10 .01
ALC >100 cells/mL 1 30
Biol Blood Marrow Transplant 17:1520-1527, 2011 1525Parainfluenza Virus Infectionscaused by PIV-1 in 1 patient, by PIV-2 in 1 patient, and
by PIV-3 in 4 patients. PIV-3 infections were not sig-
nificantly associated with LRTI (P5 .75) or mortality
(P5 1.0). Coinfections with adenovirus, RSV, Pseudo-
monas aeruginosa, andCMVwere seen in 1 patient each.
Of the 18 patients with LRTI, 3 received ribavirin
within 24 hours of diagnosis and 2 received ribivarin
after initiation of mechanical ventilation. There was
no apparent effect of ribavirin therapy on mortality
(P 5 .12) or duration of viral shedding.DISCUSSION
This retrospective study describes the clinical
characteristics of symptomatic PIV infections in chil-
dren who had undergoneHSCTover a 15-year period.
Although studies in adult HSCT patients have shown
that PIV infections are relatively common and cause
significant morbidity and mortality, the role of these
infections in immune-compromised children remains
less well understood.
In a population of otherwise healthy children in an
outpatient setting, PIV infection was cultured in 286 of
5099 samples (5.6%) collected prospectively over a 20-
year period. PIV infections caused 64% of cases of
croup, 22% of LRTI, and 20% of URTI in these
preschool-age children [7]. In a population-based
study of the inpatient burden of PIV infections,
Weinberg et al. [5] identified 191 cases of PIV
(6.8%), 529 (18.7%) cases of RSV, and 159 (5.7%)
cases of influenza in 2298 immune-competent children
with acute respiratory illness or fever. The type distri-
bution was 50% PIV-3, 38% PIV-1, and 12% PIV-2.
In our population, PIV caused infection in 6.2% of
patients with respiratory illness, more frequently than
influenza A (4.9%) andRSV (3.9%). The type distribu-
tion was 65% PIV-3, 17% PIV-1, 11% PIV-2, and 4%
PIV-4. This is similar to the distribution in otherwise
healthy children but contrasts with that in adult
HSCT recipients, with $90% PIV-3 infections [1,3].
In otherwise healthy children, PIV-1 and PIV-2
tend to occur biennially in the fall of odd-numbered
years, whereas PIV-3 occurs throughout the year,
with a peak in spring and early summer [7]. In our pop-
ulation, PIV maintained this seasonal and temporal
distribution. CA infections were observed in 72% of
our patients; however, no clustering of episodes was
seen. CA infections were reported in 78% of adult
HSCT patients with PIV infection, with 58% of these
infections occurring in clustered episodes [1]. Out-
breaks of HA infection have been reported in adult
HSCT patients as well [2,3].
The reported incidence of LRTI has ranged from
25% in a series of 222 HSCT patients with PIV infec-
tion [1] to 70% in a series of 27 HSCT patients, in-
cluding 15 children [4]. Some 39% of our patientshad LRTI, confirmedmainly by the presence of diffuse
interstitial infiltrates demonstrated on chest radiogra-
phy or chest CT andmultiple bilateral nodules in 2 pa-
tients. Multiple bilateral small nodules \10 mm in
diameter have been associated with a diagnosis of viral
pneumonitis [8]. Only 1 child presented with croup.
This contrasts with the reported incidence of croup
of 64% in otherwise healthy preschool children with
PIV infection [7]. The median duration between onset
of symptoms and diagnosis of 2 days (range, 1-7 days)
compares well with a median duration of 9 days (range,
3-60 days) using culture methods alone [4] as well as
with a median duration of 4 days (range, 0-22 days) us-
ing culture and DFA [2], where .50% of patients al-
ready had signs of LRTI before a diagnosis was made.
Culture and DFA detection were used for the en-
tire duration of the study. There were no significant
changes in the culture and DFA techniques during
this period that could have affected the sensitivity of
the test. PCR was performed on respiratory samples
obtained after February 2007. For diagnosis of the ini-
tial infection, the virus was isolated from culture in all
but 1 patient, who was identified by PCR only. PCR
tested positive with culture in all 6 patients in whom
both methods were used. One patient was detected
by PCR alone. Only 7 patients were tested by culture,
DFA, and PCR, and thus a method comparison of the
sensitivity of PCR with DFA and culture was not per-
formed. Real-time PCR provides a much more sensi-
tive test than conventional techniques for detecting
PIV, and is more rapid than viral culture [9,10]. This
assay could improve management of immune-
compromised patients by enabling prompt isolation
after early detection.
Undergoing allogeneic HSCT significantly in-
creased the risk of PIV infection in our patients. Re-
ceipt of an unrelated transplant is a reported risk
factor for PIV-3 acquisition [1]. In a smaller series of
adult HSCT patients, Elizaga et al. [2] found a similar
frequency of PIV-3 infections in allogeneic and autol-
ogous transplantations and with matched sibling do-
nors compared with unrelated donors. PIV-3
pneumonia occurs after autologous transplantation
mainly in the setting of CD34 cell selection or high-
dose steroid therapy [1].
TBI was given in 2 fractions of 1.5 Gy daily for 4
days, with lung shielding. There is evidence linking
acute idiopathic interstitial pneumonitis with TBI
even with fractionated doses [11]; however, an in-
creased risk of acquiring respiratory viral infections
has not been reported. The majority (66%) of patients
with PIV infection who had received TBI-based con-
ditioning (66%) had aURTI. The association between
TBI and PIV infection requires confirmation by fur-
ther studies.
Infection acquired before 100 days post-HSCT
was significantly associated with LRTI in our study.
1526 Biol Blood Marrow Transplant 17:1520-1527, 2011A. Srinivasan et al.Of the 24 adults who developed PIV-3 infection, 20
(83%) developed the infection within 100 days of
transplantation [2]. Infection acquired before 100
days post-HSCT also was associated with a higher fre-
quency of LRTI and increasedmortality in a retrospec-
tive study of adult HSCT recipients [3]. Use of
corticosteroids at the time of onset of infection was sig-
nificantly associated with LRTI. In one study, the cor-
ticosteroid dose at the onset of PIV-3 infection was the
primary factor associated with the development of PIV
pneumonitis [1]. It is likely that the effect of corticoste-
roids is due to a decline in T cell immunity. Chakra-
barti et al. [12] reported a probability of respiratory
virus isolation as high as 35% in adults conditioned
with a nonmyeloablative regimen that included
Campath-1H, which has a long half-life, depletes T
cells, and impedes recovery of CD41 T cells in the
early posttransplantation period.
An ALC\100 cells/mL was associated with devel-
opment of LRTI. The association of LRTI with severe
lymphopenia may reflect an increase in progression
with severe myelosuppression. Infection occurring be-
fore 100 days post-HSCT was highly correlated with
an ANC \500 cells/mL in the statistical analysis.
Time post-HSCT is likely the more meaningful inde-
pendent risk factor for LRTI. Patients with an ALC
\500 cells/mL had a more prolonged duration of viral
shedding. In a prospective study of respiratory viral in-
fections in 70 adult allogeneic HSCT recipients, 23 of
whom had an LRTI, severe lymphopenia was associ-
ated with the risk of developing LRTI [13]. That co-
hort included 1 patient with PIV-3 infection. Lewis
et al. [3] found a significantly higher rate of lymphope-
nia in patients with pneumonia compared with patients
with uncomplicated URTI, but a similar frequency of
neutropenia in the 2 groups. Late airflow obstruction
has been linked to both PIV LRTI and URTI [14].
In our series, only 2 of the 10 surviving patients with
LRTI tested demonstrated abnormalities on pulmo-
nary function testing performed 1 year after the infec-
tion, in the form of restrictive lung disease and
decreased diffusion capacity.
LRTI and the need for mechanical ventilation was
associated with increased mortality. Mortality in adult
HSCT patients was influenced by the need for me-
chanical ventilation and by the presence of copatho-
gens, which was seen in 53% of patients with LRTI
[1], compared with 17% of patients in the present se-
ries.Aspergillus fumigatuswas found in 24% of the cases
[1]. This may help explain the high 30-day mortality of
35% and 180-day mortality of 75%, compared with
17% in the present series. A high mortality of 34% as-
sociated with LRTI also was reported by Lewis et al.
[3], who found other serious concurrent infections in
70% of the deceased patients. Other factors contribut-
ing to the increased mortality in adults may include
the presence of comorbid conditions and a higherincidence of GVHD with consequent T cell suppres-
sion. Mortality also was influenced by onset of infection
before day 100 post-HSCT [1-3] and the presence of
LRTI [1,4]. Although no randomized studies have
been published to date, neither aerosolized ribavirin
nor intravenous immunoglobulin has led to improved
outcomes [1]. In the present series, we found no effect
of ribavirin on mortality or on the duration of viral
shedding. Whether preemptive treatment of URTI
with aerosolized ribavirin may prevent progression to
LRTI is unknown. Although the incidence of PIV in-
fections after reduced-intensity conditioning was
high, the mortality was only 8%, perhaps related to
the reduced regimen-related toxicity and low inci-
dence of GVHD. Given that the use of corticosteroids
was identified as a risk factor for LRTI and was associ-
ated with mortality in our series, the judicious use of
steroids may be considered in the presence of PIV
URTI.
Patients of AA ethnicity were more likely to have
received steroids before the onset of infection, which
was a risk factor for LRTI.However, the small number
of AA patients in the present series requires that the as-
sociation with increased mortality be interpreted with
caution. Further studies are needed to corroborate
whether AA ethnicity is a risk factor for mortality
from respiratory virus infections in children undergo-
ing HSCT.
Asymptomatic carriage of PIV in adult recipients
of HSCT has been noted, with a cumulative incidence
of 17.9% at day 100 post-HSCT [15]. Asymptomatic
shedding of the virus for long periods in immune-
competent adults has been observed [16]. PIV may
be present in the respiratory secretions of healthy chil-
dren without symptoms [17]. Furthermore, the virus
tends to persist on environmental surfaces for long pe-
riods [18]. These factors may predispose this virus to
outbreaks in the hospital setting. Safe and immuno-
genic bivalent vaccines for PIV-3 and RSV have been
developed [19] and are currently undergoing further
trials. A vaccine for PIV-1 and a bivalent vaccine for
PIV-1 and RSV are under development as well
[20,21]. Given that the majority of infections are CA,
with young infants as the reservoir of infection, this
strategy may prove useful.
Our study has several limitations, including its ret-
rospective nature and the small number of events per
variable. The latter, along with the relatively large
number of significant marginal risk factors, precluded
the use of multiple logistic regression analysis, which
can adjust for possible confounding factors, to evaluate
the risk for LRTI and mortality [22]. In addition, there
is ascertainment bias, given that only children with re-
spiratory symptoms were screened at the discretion of
the treating physician.
In conclusion, this is the largest retrospective study
of PIV infections in children reported to date,
Biol Blood Marrow Transplant 17:1520-1527, 2011 1527Parainfluenza Virus Infectionscomprising 1028 HSCT recipients over a 15-year pe-
riod. PIV infections occurred in 46 patients (6.2%) and
were the most common respiratory virus infections in
this population. Receipt of an allogeneic transplant
and TBI-based conditioning increased the risk for
PIV infection. Risk factors for LRTI, seen in 18 pa-
tients (39%), included infection before day 1100,
use of corticosteroids at the time of onset of infection,
and ALC \100 cells/mL. Croup was noticeably un-
common as a presenting manifestation of PIV infec-
tion. Risk factors for mortality included LRTI, use
of corticosteroids, the need for mechanical ventilation,
and ALC\100 cells/mL.Mortality fromPIV pneumo-
nia is high. New agents are needed, and until these are
developed, preventive strategies may need to focus on
surveillance of both asymptomatic and symptomatic
patients and on compliance with hand hygiene prac-
tices to prevent the spread of PIV infection.ACKNOWLEDGMENTS
We thank Mark Mestemacher from the SJCRH
clinical laboratory for assisting with data collection.
This work was supported by a National Cancer Insti-
tute Cancer Center CORE Support Grant P30 CA
21765 and by the American Lebanese Syrian Associ-
ated Charities.
Financial disclosure: The authors have no conflicts
of interest to disclose.REFERENCES
1. Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus in-
fections after hematopoietic stem cell transplantation: risk fac-
tors, response to antiviral therapy, and effect on transplant
outcome. Blood. 2001;98:573-578.
2. Elizaga J, Olavarria E, Apperley JF, et al. Parainfluenza virus 3
infection after stem cell transplant: relevance to outcome of
rapid diagnosis and ribavirin treatment. Clin Infect Dis. 2001;
32:413-418.
3. Lewis VA, Champlin R, Englund J, et al. Respiratory disease due
to parainfluenza virus in adult bone marrow transplant recipi-
ents. Clin Infect Dis. 1996;23:1033-1037.
4. Wendt CH,Weisdorf DJ, Jordan MC, et al. Parainfluenza virus
respiratory infection after bone marrow transplantation. N Engl
J Med. 1992;326:921-926.
5. WeinbergGA,Hall CB, IwaneMK, et al. Parainfluenza virus in-
fection of young children: estimates of the population-based
burden of hospitalization. J Pediatr. 2009;154:694-699.
6. PrzepiorkaD,WeisdorfD,Martin P, et al. 1994Consensus con-
ference on acuteGVHDgrading. BoneMarrow Transplant. 1995;
15:825-828.7. Reed G, Jewett PH, Thompson J, et al. Epidemiology and clin-
ical impact of parainfluenza virus infections in otherwise healthy
infants and young children\5 years old. J Infect Dis. 1997;175:
807-813.
8. Franquet T,M€uller NL,Gimenez A, et al. Infectious pulmonary
nodules in immunocompromised patients: usefulness of com-
puted tomography in predicting their etiology. J Comput Assist
Tomogr. 2003;27:461-468.
9. van Elden LJ, van Kraaij MG, Nijhuis M, et al. Polymerase
chain reaction is more sensitive than viral culture and antigen
testing for the detection of respiratory viruses in adults with he-
matological cancer and pneumonia. Clin Infect Dis. 2002;34:
177-183.
10. Weinberg A, Zamora MR, Li S, et al. The value of polymerase
chain reaction for the diagnosis of viral respiratory tract infec-
tions in lung transplant recipients. J Clin Virol. 2002;25:171-175.
11. Weshler Z, Breuer R, Or R, et al. Interstitial pneumonitis after
total body irradiation: effect of partial lung shielding. Br J
Haematol. 1990;74:61-64.
12. Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus in-
fections in transplant recipients after reduced-intensity condi-
tioning with Campath-1H: high incidence but low mortality. Br
J Haematol. 2002;119:1125-1132.
13. Martino R, Porras RP, Rabella N, et al. Prospective study of the
incidence, clinical features and outcome of symptomatic upper
and lower respiratory tract infections by respiratory viruses in
adult recipients of hematopoietic stem cell transplants for hema-
tologic malignancies. Biol Blood Marrow Transplant. 2005;11:
781-796.
14. Erard V, Chien JW, Kim, et al. Airflow decline after myeloabla-
tive allogeneic hematopoietic cell transplantation: the role of
community respiratory viruses. J Infect Dis. 2006;193:
1619-1625.
15. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infec-
tion among hematopoietic cell transplant recipients: evidence
for asymptomatic parainfluenza virus infection. Blood. 2007;
110:1681-1688.
16. Kapikian AZ, ChanockRM, Reichelderfer TE, et al. Inoculation
of human volunteers with parainfluenza virus type 3. JAMA.
1961;178:537-541.
17. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of
myxoviruses and paramyxoviruses in children. J Infect Dis.
1981;144:433-441.
18. Brady MT, Evans J, Cuartas J. Survival and disinfection of para-
influenza viruses on environmental surfaces. Am J Infect Control.
1990;18:18-23.
19. Belshe RB, Newman FK, Anderson EL, et al. Evaluation of
combined live, attenuated respiratory syncytial virus and parain-
fluenza 3 virus vaccines in infants and young children. J Infect
Dis. 2004;190:2096-2103.
20. Slobod K, Shenep J, Lujan-Zilbermann J, et al. Safety and im-
munogenicity of intranasal murine parainfluenza virus type 1
(Sendai virus) in healthy human adults. Vaccine. 2004;22:
3182-3186.
21. Hurwitz J. Development of recombinant Sendai virus vaccines
for prevention of human parainfluenza and respiratory syncy-
tial virus infections. Pediatr Infect Dis J. 2008;27(Suppl):
S126-S128.
22. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the
number of events per variable in logistic regression analysis.
J Clin Epidemiol. 1996;49:1373-1379.
